Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Alpha-Amylase Inhibitor - Pipeline Insight, 2025
... for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages Clinical ... Read More
-
Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2025
... including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global ... Read More
-
Angiotensin Modulators - Pipeline Insight, 2025
... for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages Clinical ... Read More
-
Arginine Depletors - Pipeline Insight, 2025
... for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages Clinical ... Read More
-
Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
-
Interleukin-4 (IL-4) Inhibitor - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
-
Interleukin-8 (IL-8) Inhibitor - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
-
Kv1.3/1.5 Potassium Channel Blockers - Pipeline Insight, 2025
... of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the ... Read More
-
Inclusion Body Myositis- Pipeline Insight, 2025
... products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Inclusion Body Myositis: Understanding ... Read More
-
Advanced Melanoma - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Advanced Melanoma: Understanding Advanced Melanoma: ... Read More
-
Myeloproliferative Disorders Drugs
... at a CAGR of 4.3% over the analysis period 2024-2030. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$9.2 Billion by ... Read More
-
Eye Allergy Therapeutics
... at a CAGR of 5.5% over the analysis period 2024-2030. Antihistamines, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$2.2 Billion by the end of the ... Read More
-
Endometriosis Drugs
... CAGR of 3.0% over the analysis period 2024-2030. Hormone therapy, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.2 Billion by the end of the analysis ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
Fibromyalgia Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Antiepileptics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. ... Read More
-
ADME-Toxicology Testing
... CAGR of 11.2% over the analysis period 2024-2030. Cell Culture, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$9.6 Billion by the end of the analysis ... Read More
-
Cancer Cachexia
... CAGR of 5.7% over the analysis period 2024-2030. Progestogens, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
Respiratory Syncytial Virus (RSV) Therapeutics
... Billion by 2030, growing at a CAGR of 29.2% over the analysis period 2024-2030. Prophylaxis, one of the segments analyzed in the report, is expected to record a 28.4% CAGR and reach US$7.6 Billion by ... Read More
-
Scleroderma Diagnostics and Therapeutics
... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Localized, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$1.9 Billion by the end ... Read More
-
Liver Diseases Treatment
... at a CAGR of 10.5% over the analysis period 2024-2030. Anti-Rejection Drugs/Immunosupressants, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$6.3 Billion by the end of ... Read More
-
Neuroprotection Therapeutics
... CAGR of 6.9% over the analysis period 2024-2030. Free Radical Trapping Agents (Antioxidants), one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$45.7 Billion by the end ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Myelodysplastic Syndrome (MDS) Drugs
... 2030, growing at a CAGR of 9.3% over the analysis period 2024-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$2.7 Billion by the ... Read More
-
Compound Management
... CAGR of 16.8% over the analysis period 2024-2030. Compound Management Instruments, one of the segments analyzed in the report, is expected to record a 17.1% CAGR and reach US$752.6 Million by the end of the ... Read More
-
Chiral Technology
... CAGR of 3.6% over the analysis period 2024-2030. Intermediates, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$8.2 Billion by the end of the analysis period. ... Read More
Research Assistance
